drugset

drugset / Trial / NCT00201812

Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors

NCT00201812 ↗

Phase 1 Completed 27 enrolled Ohio State University Comprehensive Cancer Center Immunex Corporation · collab

NaSingle-groupOpen-labelTreatment

Summary

To determine the safety and efficacy of the combination of Etanercept and Docetaxel in patients with advanced solid tumors for which there is no standard treatment.

Timeline

Start: 2000-11
Primary completion: 2004-01
Completion: 2005-05

Publications

Results Monk JP, Phillips G, Waite R, Kuhn J, Schaaf LJ, Otterson GA, Guttridge D, Rhoades C, Shah M, Criswell T, Caligiuri MA, Villalona-Calero MA. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol. 2006 Apr 20;24(12):1852-9. doi: 10.1200/JCO.2005.04.2838.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Docetaxel	Small molecule	43 mg/m2	Intravenous
Subject	Docetaxel	Small molecule	52 mg/m2	Intravenous
Subject	Etanercept	Protein / enzyme biologic	25 mg	Subcutaneous
Background	Dexamethasone	Small molecule	8 mg	Oral

Indications